Results of Vac-4x HIV vaccine announced

Researchers with the Oslo University and Bionor Immuno at the XVIII International AIDS Conference in Vienna, Austria, recently released the results of a re-vaccination study of Norway’s largest hospital using the company's furthest advance HIV vaccine candidate, Vac-4x.

Researchers said 26 of the 40 HIV patients from a 2002-2003 phase IIa study were re-vaccinated between January and June 2010. The 22 patients were studied prior to a voluntary "re-boost" of Vacc-4x. Results from the reboost of the 26 patients are expected in August or September.

“The Vacc-4x immunization technology using short peptide analogues to conserved viral protein domains has shown not only development of surprisingly long-term immunological memory T cells in these immunocompromised patients, but also that viral sequences changes during intermittent treatment interruptions were negligible,” Professor Dag Kvale, co-author of the study, said.

Birger Sørensen, Bionor Immuno's CEO, agreed.

“Given this new data, and because Vacc-4x is comprised of four modified peptides that target conserved domains of the HIV p24 protein, we are especially optimistic about our ability to control HIV,” Sørensen said. “The research indicates that the vaccine is stimulating an immune response seven years after injection, which is, in itself, unprecedented in HIV. But we know we have more work to do.”